27020933
Descrição
Mapa Mental por Karla Gonzalez Negrete, atualizado more than 1 year ago
|
Criado por Karla Gonzalez Negrete
mais de 3 anos atrás
|
|
Use of a humanized Anti-CD6 monoclonal antibody in
elderly patients with moderate COVID-19
- Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a
recent outbreak of coronavirus disease (COVID-19). In Cuba, the first case of
COVID-19 was reported on March11,2020.
- Erderly individuals with multiple comorbilities are particularly sesceptible to adverse clinical
outcomes in the course of SARS-CoV-2 infection. During the outbreak, a local transmission
event took place in a nursing home in Villa Clara province, Cuba in whitch 19 elderly
residents tested positive for SARS-CoV-2.
- 19 patients were included in an expanded
access clinical trial to receive itolizumab, an
anti-CD6 monoclonal antibody.
- To preeliminary assess the effect of itolizumab, a control group was
selected among the Cuba COVID-19 patients that did not receive
immunomodulatory therapy. The control subjects were well matched
regarding age, comorbilities, and severity of the sisease.
- Additionally, treatment with itolizumab reduced the risk of death
10 times as compared with the control group.
- This study corroborates that the timely use of
itolizumab in combination with other antivirals
reduces COVID-19 disease worsening and mortality.
Quer criar seus próprios Mapas Mentais gratuitos com a GoConqr? Saiba mais.